Janssen’s newly-merged infectious disease and vaccine unit sees significant pipeline cuts

The company posted a significantly slimmed-down pipeline for the unit Thursday morning ahead of a third-quarter earnings call, shaving off all hepatitis work and additional assets targeting HIV and influenza. All that remains are approved HIV treatments Cabenuva and Edurant, vaccines for COVID, E.coli and ebola, as well as Remicade as a treatment for COVID.